Viking Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Viking Therapeutics, Inc. (VKTX) reported Increase Decrease In Operating Lease Liability of -$330.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-29
- Viking Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$191.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$139.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$116.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$130.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$505.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$402.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$347.00K.
- Viking Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$189.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$191.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$330.00K 10-Q · filed 2026-07-29 | -$446.00K derived: sum of 3 quarters · filed 2026-07-29 | -$576.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$139.00K 10-Q · filed 2026-04-30 | -$255.00K derived: sum of 2 quarters · filed 2026-04-30 | -$385.00K derived: sum of 3 quarters · filed 2026-04-30 | -$515.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$246.00K derived: sum of 2 quarters · filed 2026-02-11 | -$376.00K derived: sum of 3 quarters · filed 2026-07-29 | -$505.00K 10-K · filed 2026-02-11 |
| 2025-09-30 | -$130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$260.00K derived: sum of 2 quarters · filed 2026-07-29 | -$389.00K 10-Q · filed 2025-10-23 | -$517.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$259.00K 10-Q · filed 2026-07-29 | -$387.00K derived: sum of 3 quarters · filed 2026-07-29 | -$483.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$129.00K 10-Q · filed 2026-04-30 | -$257.00K derived: sum of 2 quarters · filed 2026-04-30 | -$353.00K derived: sum of 3 quarters · filed 2026-04-30 | -$443.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$224.00K derived: sum of 2 quarters · filed 2026-02-11 | -$314.00K derived: sum of 3 quarters · filed 2026-02-11 | -$402.00K 10-K · filed 2026-02-11 |
| 2024-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$186.00K derived: sum of 2 quarters · filed 2025-10-23 | -$274.00K 10-Q · filed 2025-10-23 | -$361.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | -$178.00K 10-Q · filed 2025-07-23 | -$265.00K derived: sum of 3 quarters · filed 2026-02-11 | -$352.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$88.00K 10-Q · filed 2025-04-24 | -$175.00K derived: sum of 2 quarters · filed 2026-02-11 | -$262.00K derived: sum of 3 quarters · filed 2026-02-11 | -$350.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$174.00K derived: sum of 2 quarters · filed 2026-02-11 | -$262.00K derived: sum of 3 quarters · filed 2026-02-11 | -$347.00K 10-K · filed 2026-02-11 |
| 2023-09-30 | -$87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | -$175.00K derived: sum of 2 quarters · filed 2024-10-23 | -$260.00K 10-Q · filed 2024-10-23 | -$344.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$173.00K 10-Q · filed 2024-07-24 | -$257.00K derived: sum of 3 quarters · filed 2025-02-26 | -$369.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$85.00K 10-Q · filed 2024-04-25 | -$169.00K derived: sum of 2 quarters · filed 2025-02-26 | -$281.00K derived: sum of 3 quarters · filed 2025-02-26 | -$198.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$196.00K derived: sum of 2 quarters · filed 2025-02-26 | -$113.00K derived: sum of 3 quarters · filed 2025-02-26 | -$189.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | -$29.00K derived: sum of 2 quarters · filed 2023-10-25 | -$105.00K 10-Q · filed 2023-10-25 | -$191.00K derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $7.00K 10-Q · filed 2023-07-26 | -$79.00K derived: sum of 3 quarters · filed 2024-02-07 | -$164.00K derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | -$76.00K 10-Q · filed 2023-04-26 | -$162.00K derived: sum of 2 quarters · filed 2024-02-07 | -$247.00K derived: sum of 3 quarters · filed 2024-02-07 | -$333.00K derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | -$171.00K derived: sum of 2 quarters · filed 2024-02-07 | -$257.00K derived: sum of 3 quarters · filed 2024-02-07 | -$342.00K 10-K · filed 2024-02-07 |
| 2021-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | -$171.00K derived: sum of 2 quarters · filed 2022-10-26 | -$256.00K 10-Q · filed 2022-10-26 | -$341.00K derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | -$86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$171.00K 10-Q · filed 2022-07-27 | -$256.00K derived: sum of 3 quarters · filed 2022-07-27 | -$339.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | -$85.00K 10-Q · filed 2022-04-27 | -$170.00K derived: sum of 2 quarters · filed 2022-04-27 | -$253.00K derived: sum of 3 quarters · filed 2022-04-27 | |
| 2020-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$168.00K derived: sum of 2 quarters · filed 2022-02-09 | -$333.00K 10-K · filed 2022-02-09 | |
| 2020-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$248.00K 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$165.00K 10-Q · filed 2021-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |